Role of antibody-based therapy in indolent non-Hodgkin's lymphoma

Monoclonal antibodies (mAb) for indolent non-Hodgkin's lymphoma (iNHL) including follicular and marginal zone lymphomas was a key therapeutic development that changed the natural history of these diseases. Rituximab, a chimeric anti-CD20 mAb, was the first immunotherapy ever used in cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Willard, Patrick, McKay, John, Yazbeck, Victor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569585/
https://www.ncbi.nlm.nih.gov/pubmed/34765437
http://dx.doi.org/10.1016/j.lrr.2021.100275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569585/
https://www.ncbi.nlm.nih.gov/pubmed/34765437
http://dx.doi.org/10.1016/j.lrr.2021.100275

Ejemplares similares